Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilparencel - inRegen

Next Previous
X
Search
Drug Profile

Rilparencel - inRegen

Alternative Names: Autologous cultured kidney tissue cells - inRegen; Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA; ReACT; REACT™; Regenerative autologous cell therapy; Renal Autologous Cell Therapy

Latest Information Update: 19 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tengion
  • Developer inRegen; ProKidney
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders; Type 2 diabetes mellitus
  • No development reported Renal failure

Most Recent Events

  • 31 Oct 2024 ProKidney attends type II meeting with the US FDA to discuss updates to Rilparencel’s registrational trial strategy
  • 03 Sep 2024 ProKidney terminates a phase III PROACT 2 trial in Renal failure and Type II diabetes mellitus in Austria, Spain and Portugal as trial is not required for initial USA registration (NCT05286853)
  • 13 Jun 2024 Prokidney initiates enrolment in the phase III trial for Kidney disorders (In adults, In the elderly) in Australia, Canada, Taiwan, United Kingdom and the USA (NCT05099770)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top